The implementation of androgen receptor signaling inhibitors (ARSIs) and other agents (e.g., docetaxel [DOC]) as an effective treatment for advanced PCa, may also potentially broaden therapeutic choices in BCR [12]. The gene discussed is BCR; the disease is posterior cortical atrophy.